Skip to main content
SpringerLink
Log in

Treatment of Hepatic Encephalopathy

  • Chapter
  • First Online:
Clinical Investigation of Portal Hypertension

Abstract

Hepatic encephalopathy (HE) is predominantly induced by a portosystemic shunt as a complication of excessive portal hypertension. Initial treatments for HE involve the identification and improvement of the causal triggers, such as infection, constipation, dehydration, and gastrointestinal bleeding. A majority of the pharmacotherapies are aimed at decreasing the production of ammonia. Lactulose alters gastrointestinal pH by favoring lactobacilli over urease-containing bacteria and enhances the production of nonabsorbable ammonia. Furthermore, these laxatives enhance fecal nitrogen excretion. Although neomycin was the first antibiotic to be effective in the treatment of HE, its use has been limited because of ototoxicity and nephrotoxicity. Recently, rifaximin, a minimally absorbable oral antibiotic, which is available in many countries, has been used in lactulose resistance encephalopathy. When used in conjunction with lactulose, rifaximin has been shown to reduce recurrent encephalopathy and hospitalization. Supplementation of branched-chain amino acids is also beneficial for patients with HE because of their stimulatory effect on ammonia detoxification to glutamine. Balloon-occluded retrograde transvenous obliteration is recommended for patients with refractory HE especially caused by portosystemic shunt. Liver transplantation is eventually performed in patients who are resistant to the abovementioned pharmacological and interventional therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716–21.

    Article  Google Scholar 

  2. American Association for the Study of Liver D, European Association for the Study of the L. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61(3):642–59.

    Article  Google Scholar 

  3. Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51(7):629–50.

    Article  CAS  Google Scholar 

  4. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25(2):285–94.

    Article  CAS  Google Scholar 

  5. Okita M. Chronic hepatic disease and dietary instruction. Hepatol Res. 2004;30S:92–5.

    Article  Google Scholar 

  6. Patel VC, White H, Stoy S, Bajaj JS, Shawcross DL. Clinical science workshop: targeting the gut-liver-brain axis. Metab Brain Dis. 2016;31(6):1327–37.

    Article  Google Scholar 

  7. Weber FL Jr, Banwell JG, Fresard KM, Cummings JH. Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin. J Lab Clin Med. 1987;110(3):259–63.

    PubMed  Google Scholar 

  8. van Leeuwen PA, van Berlo CL, Soeters PB. New mode of action for lactulose. Lancet. 1988;1(8575–6):55–6.

    Article  Google Scholar 

  9. Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology. 1992;15(2):222–8.

    Article  CAS  Google Scholar 

  10. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044.

    PubMed  Google Scholar 

  11. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepato-gastroenterology. 1992;39(6):542–5.

    CAS  PubMed  Google Scholar 

  12. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity—a review. Chemotherapy. 2005;51(Suppl 1):67–72.

    Article  CAS  Google Scholar 

  13. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  CAS  Google Scholar 

  14. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011;140(2):478–87.e1.

    Article  CAS  Google Scholar 

  15. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18(8):767–77.

    Article  CAS  Google Scholar 

  16. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–63.

    Article  CAS  Google Scholar 

  17. Kimer N, Krag A, Moller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40(2):123–32.

    Article  CAS  Google Scholar 

  18. Dam G, Ott P, Aagaard NK, Vilstrup H. Branched-chain amino acids and muscle ammonia detoxification in cirrhosis. Metab Brain Dis. 2013;28(2):217–20.

    Article  CAS  Google Scholar 

  19. Gluud LL, Dam G, Les I, Cordoba J, Marchesini G, Borre M, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015;2:CD001939.

    Google Scholar 

  20. Riggio O, Merli M, Capocaccia L, Caschera M, Zullo A, Pinto G, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology. 1992;16(3):785–9.

    Article  CAS  Google Scholar 

  21. Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura SI, Watanabe A, et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama. 2001;55(6):349–55.

    CAS  PubMed  Google Scholar 

  22. Krahenbuhl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology. 1997;25(1):148–53.

    CAS  PubMed  Google Scholar 

  23. Shiraki M, Shimizu M, Moriwaki H, Okita K, Koike K. The carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients. Hepatol Res. 2017;47(4):321–7.

    Article  CAS  Google Scholar 

  24. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46(6):1853–62.

    Article  CAS  Google Scholar 

  25. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996;11(1):51–8.

    Article  CAS  Google Scholar 

  26. Kato T, Uematsu T, Nishigaki Y, Sugihara J, Tomita E, Moriwaki H. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis. Intern Med. 2001;40(8):688–91.

    Article  CAS  Google Scholar 

  27. Ohmoto K, Miyake I, Tsuduki M, Ohno S, Yamamoto S. Control of solitary gastric fundal varices and portosystemic encephalopathy accompanying liver cirrhosis by balloon-occluded retrograde transvenous obliteration (B-RTO): a case report. Hepato-Gastroenterology. 1999;46(26):1249–52.

    CAS  PubMed  Google Scholar 

  28. Uehara H, Akahoshi T, Tomikawa M, Kinjo N, Hashimoto N, Nagao Y, et al. Prediction of improved liver function after balloon-occluded retrograde transvenous obliteration: relation to hepatic vein pressure gradient. J Gastroenterol Hepatol. 2012;27(1):137–41.

    Article  Google Scholar 

  29. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37, 37.e1–9.

    Article  Google Scholar 

  30. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan

    Kosuke Kaji, Norihisa Nishimura, Kei Moriya & Hitoshi Yoshiji

Authors
  1. Kosuke Kaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norihisa Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kei Moriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hitoshi Yoshiji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kosuke Kaji .

Editor information

Editors and Affiliations

  1. Department of Advanced Gastrointestinal Endoscopy, Fukushima Medical University, Fukushima, Japan

    Katsutoshi Obara

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaji, K., Nishimura, N., Moriya, K., Yoshiji, H. (2019). Treatment of Hepatic Encephalopathy. In: Obara, K. (eds) Clinical Investigation of Portal Hypertension. Springer, Singapore. https://doi.org/10.1007/978-981-10-7425-7_55

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7425-7_55

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7424-0

  • Online ISBN: 978-981-10-7425-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation